DNA错配修复基因甲基化在肝细胞癌发生发展中的作用

目的探讨DNA错配修复基因(MMR)hMLH1,hMSH2和hMSH3甲基化在肝细胞癌(HCC)发生发展中的作用。方法采用甲基化特异性聚合酶链反应(MSP)法对38例新鲜HCC组织,相应非肿瘤肝组织,2例正常的捐肝组织及6种肝癌细胞系的hMLH1,hMSH2和hMSH3基因启动子CpG岛甲基化进行检测;培养6种肝癌细胞系,MSP法检测加入5-aza-2‘-deoxycytidine前后hMSH2基因在HCC中的甲基化状态改变;逆转录．聚合酶链反应(RT-PCR)方法检测加入5-aza-2’-deoxycytidine前后hMSH2在肝癌细胞株中的mRNA表达改变。结果HCC标本中13．2％(5／38)发生了hMLH1启动子甲基化,68．4％(26／38)发生了hMSH2启动子甲基化;相应的非肿瘤肝组织中hMLH1,hMSH2启动子甲基化阳性率分别为2．6％(1／38),55．3％(21／38);2例正常肝组织中未发现甲基化;6株肝癌细胞系中有5株发生了hMSH2启动子甲基化,而未发现有MLH1启动子甲基化。所有标本中均未发现有hMSH3启动子甲基化。5-aza-2‘-deoxycytidine处理细胞株后,可部分或完全逆转hMSH2启动子甲基化,各细胞株的mRNA均有不同程度的表达增加。结论hMSH3基因启动子CpG岛甲基化与HCC的发生发展关系不大。hMSH2基因甲基化与mRNA表达密切相关,是基因表达调节的一种重要方式。hMLH1和hMSH2基因启动子CpG岛的高甲基化在HCC中是一个常见的基因改变,DNA错配修复基因尤其是hMSH2基因启动子甲基化在HCC的发生中起了重要作用,是早期事件,其可能为临床诊断HCC提供新的检测指标。     

126例子宫内膜癌中Lynch综合征的初步筛查

目的探讨hMSH2、hMSH6、hMLH1、hPMS2蛋白缺失情况和hMLH1基因启动子甲基化状态及Lynch综合征患者的家系分析,初步进行Lynch综合征相关子宫内膜癌筛查。方法采用免疫组化SP法检测126例子宫内膜癌中hMSH2、hMSH6、hMLH1、hPMS2蛋白表达,并用甲基化特异性PCR检测hMLH1蛋白表达缺失病例的hMLH1基因启动子甲基化状态。结果免疫组化结果显示22%(28/126)的病例出现MMR蛋白缺失表达,其中12例hMLH1~-/hPMS2~-、6例hPMS2~-、4例hMSH2~-/hMSH6~-,hMSH6~-和hMLH1~-各3例,以hMLH1和hPMS2蛋白缺失表达为主。甲基化特异性PCR检测有hMLH1蛋白表达缺失的15例子宫内膜癌中hMLH1基因启动子甲基化状态,证实9例存在hMLH1基因启动子甲基化,提示其为子宫内膜癌的散发性病例。结论对子宫内膜癌患者行MMR蛋白免疫组化SP法染色,结合甲基化特异性PCR检测hMLH1基因启动子甲基化状态,是初步筛查Lynch综合征的有效策略。     

哈族食管鳞癌中PLCE1基因启动子甲基化水平的实验研究

目的探讨PLCE1基因启动子甲基化与食管鳞癌发生发展的关系。方法分别用免疫组化(IHC)和甲基化特异PCR(MSP)方法检测51例新疆哈萨克族食管鳞癌及相应癌旁正常组织中PLCE1蛋白表达水平及其启动子甲基化水平,分析其与病理资料相关性;分别用Western blot及MSP检测食管鳞癌细胞在5-aza-dC作用前后PLCE1蛋白表达及启动子甲基化变化情况。结果新疆哈萨克族食管鳞癌组织中PLCE1蛋白表达高于癌旁正常组织,而其基因甲基化水平则较低(P 0.001),且蛋白高表达的癌组织中其甲基化水平低于蛋白低表达的癌组织(P=0.028),PLCE1甲基化水平与其蛋白表达水平具有明显的相关性(χ~2=4.791,P=0.028),并与患者的淋巴结及远处转移(χ~2=7.242,P=0.027)和TNM分期(χ~2=7.883,P=0.019)明显相关;在食管鳞癌细胞系中PLCE1甲基化程度同样与蛋白表达水平成反比,5-aza-dC处理可抑制TE-1和Kyse150的PLCE1甲基化,提高其蛋白表达。结论食管鳞癌组织中PLCE1甲基化低与其蛋白表达高、淋巴结和远处转移及TNM分期相关,5-aza-dC处理可抑制PLCE1甲基化程度,增高其蛋白表达。     

原发胃癌中p16和p15基因表达及甲基化异常

为检测胃癌组织中抑癌基因p16,p15及其启动子区甲基化状态和P16、P15蛋白表达情况。选择p16、p15基因及启动子区域，用PCR－SSCP、MSP（甲基化特异的PCR）和测序法对100例胃癌患者的癌组织、癌旁正常组织和5例正常组织进行检测，同时用免疫组化法检测了癌组织和正常对照组织的P16和P15的表达。结果发现癌组织p16和p15基因启动子区甲基化率显著高于癌旁正常组织和正常对照；胃癌组织中，71％的病例P16表达阴性，54％的病例具有p16基因启动子区的高甲基化，无突变和纯合缺失检出；11％的病例P15表达阴性，9％的病例具有p15基因启动子区的高甲基化，p15异常与低分化胃癌有关，p15基因内含子1和外显子1内各发现1例DNA序列改变；癌组织中p16和p15基因启动子区甲基化与其蛋白表达密切相关。结果显示p16基因启动子区域高甲基化是胃癌中p16基因失活的关键因素之一，并在胃癌的发生发展中发挥重要作用；p15基因启动子区域高甲基化在胃癌中起一定作用。     

脑胶质瘤患者组织和血清MGMT、hMLH1和hMSH2基因启动子甲基化状态检测

目的 探讨脑胶质瘤患者组织和血清中MGMT、hMLH1和hMSH2基因启动子CpG岛甲基化发生率及相关性.方法 甲基化特异性PCR(MSP)检测39例脑胶质瘤组织样本及32例预处理的脑胶质瘤血清样本中MGMT、hMLH1和hMSH2基因启动子区的甲基化状态.结果 脑胶质瘤组织MGMT、hMLH1和hMSH2基因启动子区甲基化发生率分别为46.2 %、10.3 % 和20.5 %,肿瘤组织中至少有一种基因甲基化的发生率为64.1 % (25/39);在脑胶质瘤患者外周循环血液中检测到了相关基因甲基化系列,并且与组织中基因甲基化发生率明显相关.结论 MGMT、hMLH1和hMSH2基因启动子甲基化是脑胶质瘤发生过程中常见的分子事件,血清中相关基因DNA甲基化检测有可能为脑胶质瘤诊断和个体化化疗提供一种稳定的无创性检测指标.     

上皮型钙粘素在宫颈鳞癌及癌前病变组织中的表达及其基因启动区CpG岛甲基化研究

目的 检测上皮型钙粘素及其基因启动区CpG岛甲基化在宫颈癌组织及癌前病变组织中的表达及其在宫颈癌发病、侵袭和转移中的作用和意义.方法 选择中南大学湘雅医院附属二院2006年10月～2009年10月40例宫颈鳞癌、52例宫颈上皮内瘤样病变(CINs)、18例正常宫颈.采用免疲组织化学法和甲基化特异PCR(MSP)法,检测E-cadherin蛋白表达及其基因启动子CpG岛甲基化状况.结果 正常宫颈组织一CINs-鳞癌,这一演变过程中各组E-cad蛋白膜表达的阳性率和甲基化率分别为100%、61%、15%;0、28%、62.5%、100%分别呈降低和升高的趋势,各组比较差异均具有统计学意义(P<0.05,P<0.01)且与临床分期和病理分级(p<0.05);宫颈癌甲基化组(1/25))低于非甲基化组(5/15),两者比较差异有统计学意义(P<0.01).结论 E-cad蛋白表达失活使其丧失了押癌作用是宫颈癌发生、发展、转移的早期信号;其启动区CpG岛甲基化是E-cad蛋白灭活的机制之一.     

上皮型钙粘素在宫颈鳞癌及癌前病变组织中的表达及其基因启动区CpG岛甲基化研究

目的检测上皮型钙粘素及其基因启动区CpG岛甲基化在宫颈癌组织及癌前病变组织中的表达及其在宫颈癌发病、侵袭和转移中的作用和意义。方法选择中南大学湘雅医院附属二院2006年10月～2009年10月40例宫颈鳞癌、52例宫颈上皮内瘤样病变（CINs）、18例正常宫颈。采用免疫组织化学法和甲基化特异PCR（MSP）法,检测E-cadherin蛋白表达及其基因启动子CpG岛甲基化状况。结果正常宫颈组织-CINs-鳞癌,这一演变过程中各组E-cad蛋白膜表达的阳性率和甲基化率分别为100%、61%、15%;0、28%、62.5%、100%分别呈降低和升高的趋势,各组比较差异均具有统计学意义（P〈O.05,P〈0.01）且与临床分期和病理分级（P〈O.05）;宫颈癌甲基化组（1/25））低于非甲基化组（5/15）,两者比较差异有统计学意义（P〈O.01）。结论 E-cad蛋白表达失活使其丧失了抑癌作用是宫颈癌发生、发展、转移的早期信号;其启动区CpG岛甲基化是E-cad蛋白灭活的机制之一。     

肺癌患者RASSF1A启动子甲基化状态及其基因表达水平

目的探讨肺癌RAS相关区域家族1A(RASSF1A)启动子CpG岛甲基化状态和基因表达水平与肺癌发生的关系。方法用甲基化特异性PCR检测RASSF1A启动子CpG岛甲基化状态,实时定量PCR检测RASSF1A mRNA的表达水平。结果在肺癌组织中RASSF1A启动子甲基化频率为53.33%(24/45),在正常肺组织中发生甲基化的频率为13.04%(3/23)(P<0.05)。正常肺组织中RASSF1A mRNA全部表达,肺癌组织中表达缺失率为28.89%(13/45),且表达量低于正常肺组织(P<0.05);不同年龄、性别、肿瘤大小、恶性程度、肿瘤分类中其表达量无显著差异;RASSF1A甲基化与其mRNA表达水平下降密切相关。结论肺癌中RASSF1A基因启动子甲基化频率明显升高,其表达普遍下调或缺失,提示RASSF1A启动子甲基化在肺癌发生、发展中起一定作用。     

维吾尔族妇女宫颈病变组织中HPV感染与低相对分子质量蛋白酶体2和7基因启动子甲基化的关系

目的 探讨维吾尔族妇女宫颈病变及其人乳头状瘤病毒( human papillomavirus,HPV)感染与低相对分子质量蛋白酶体(low molecular-weight protein,LMP)基因启动子区甲基化水平的关系和意义.方法 利用专业软件设计LMP2和LMP7基因启动子区含CpG岛特异性PCR引物,对SiHa宫颈癌细胞DNA进行亚硫酸氢盐修饰、目的片段扩增、质粒载体克隆和测序,确定该区域所含CpG序列甲基化情况;收集维吾尔族妇女正常宫颈上皮、宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)和宫颈鳞癌(cervical squamous cell carcinoma,CSCC)患者新鲜组织和石蜡组织标本78例,并提取DNA,采用Sequenom MassARRAY DNA技术平台(质谱分析),定量分析LMP2和LMP7基因启动子甲基化水平,同时以HPV分型芯片鉴定HPV亚型,分析基因甲基化与HPV感染的关系;应用RT-PCR和免疫组织化学方法检测LMP2、LMP7mRNA和蛋白的表达,并分析蛋白表达与基因甲基化的关系.结果 LMP2和LMP7基因相应目的片段各含有22个CpG位点,在SiHa宫颈癌细胞基因组DNA中,只有LMP7有2个位点发生甲基化.宫颈病变病理过程伴随着LMP7基因CpG片段甲基化水平改变,其在CSCC和CIN组织的甲基化率(0.1864±0.0893和0.0728±0.0548)高于正常宫颈上皮组织(0.0652±0.0488),差异有统计学意义(P＜0.05).随着宫颈病变的加重LMP7 mRNA和蛋白表达逐渐下调,各组间表达差异具有统计学意义(P＜0.05),LMP7蛋白表达随着该基因甲基化率增高而降低(F=8.69,P=0.035).而LMP2蛋白表达在3组间差异无统计学意义(P＞0.05).HPV分型芯片检出12种HPV基因型,其中HPV16感染率构成比为52/78(66.7％),HPV16亚型阳性与宫颈病变进程及LMP7基因甲基化率升高趋势正相关(t=1.996,P=0.049).结论 LMP7基因启动子区CpG岛甲基化是一种宫颈癌病变特异性改变,与HPV16感染可能存在密切关系.     

CTSS在宫颈癌中的表达及临床意义

目的探讨组织蛋白酶S(CTSS)在宫颈癌组织中的表达与宫颈癌发生发展的关系。方法收集39例宫颈鳞癌组织、71例宫颈上皮内瘤样变组织(CIN)及35例正常宫颈上皮组织,经常规方法提取RNA及蛋白,RT-PCR方法检测CTSS mRNA表达水平,Western Blot检测CTSS蛋白表达水平。结果 CTSS蛋白和mRNA在正常宫颈上皮组织、宫颈上皮内瘤样变组织和宫颈鳞癌组织中的表达依次增高,三者之间相比,差异有统计学意义(0.05)。CTSS蛋白和mRNA在低分化鳞癌组织中的表达明显高于高分化鳞癌组织(0 05),与宫颈癌的组织学分级呈正相关。结论 CTSS在宫颈癌发生、发展过程中起重要作用,有可能成为预测HCC侵袭转移的新指标。     

Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC

We previously showed that silencing of TSLC1, recently renamed CADM1, is functionally involved in high-risk HPV-mediated cervical carcinogenesis. CADM1 silencing often results from promoter methylation. Here, we determined the extent of CADM1 promoter methylation in cervical (pre)malignant lesions and its relation to anchorage-independent growth and gene silencing to select a CADM1-based methylation marker for identification of women at risk of cervical cancer. Methylation-specific PCRs targeting three regions within the CADM1 promoter were performed on high-risk HPV-containing cell lines, PBMCs, normal cervical smears, and (pre)malignant lesions. CADM1 protein expression in cervical tissues was analysed by immunohistochemistry. All statistical tests were two-sided. Density of methylation was associated with the degree of anchorage-independent growth and CADM1 gene silencing in vitro. In cervical squamous lesions, methylation frequency and density increased with severity of disease. Dense methylation (defined as >or= 2 methylated regions) increased from 5% in normal cervical samples to 30% in CIN3 lesions and 83% in squamous cell carcinomas (SCCs) and was significantly associated with decreased CADM1 protein expression (p < 0.00005). The frequency of dense methylation was significantly higher in >or= CIN3 compared with or= CIN3.     

Retinoic acid receptor beta promoter methylation and risk of cervical cancer

Cervical cancer is one of the leading causes of death in women worldwide, particularly in developing countries. Human papillomavirus has been reported as one of the key etiologic factors in cervical carcinoma. Likewise, epigenetic aberrations have ability to regulate cancer pathogenesis and progression. Recent research suggested that methylation has been detected already at precancerous stages, which methylation markers may have significant value in cervical cancer screening. The retinoic acid receptor beta (RARβ) gene, a potential tumor suppressor gene, is usually expressed in normal epithelial tissue. Methylation of CpG islands in the promoter region of the RARβ gene has been found to be associated with the development of cervical cancer. To investigate whether RARβ methylation is a potential biomarker that predicts the progression of invasive cancer, we reviewed 14 previously published articles related to RARβ methylation. The majority of them demonstrated that the frequency of RARβ promoter methylation was significantly correlated with the severity of cervical epithelium abnormalities. However, methylation of a single gene may not represent the best approach for predicting disease prognosis. Analyzing combinations of aberrant methylation of multiple genes may increase the sensitivity, and thus this approach may serve as a better tool for predicting disease prognosis.     

Effect of 5-azacytidine (5-aza) on UCP2 expression in human liver and colon cancer cells

The function of the uncoupling protein 2 (UCP2) is different for each cancer cell. However, the mechanism of expression is still unclear. DNA methylation affects protein expression and is one factor that transforms normal cells into cancer cells. In this study, the hepatocellular carcinoma Hep3B and HepG2 cells and colorectal cancer HT-29 cells were treated with 5-azacytidine (5-aza), a DNA demethylation agent, to observe the modification of UCP2 expression and the methylation degree in the UCP2 promoter region. Promoter basal activity and degree of UCP2 expression were measured in Hep3B, HepG2, and HT-29 cells. In addition, methylation-specific PCR (MSP) was performed to investigate the degree of methylation in the UCP2 promoter region. The methylation region in the UCP2 promoter was confirmed based on bisulfite sequencing. In Hep3B cells in which UCP2 mRNA was not transcribed, the promoter basal activity was significantly higher than in HT-29 or HepG2 cells in which UCP2 mRNA was transcribed. Treatment with 5-aza increased UCP2 expression in Hep3B and HT-29 cells; however, the expression in HepG2 cells was unchanged. The UCP2 promoter in Hep3B cells has numerous methylated regions compared with HT-29 and HepG2 cells. The results of the present study revealed that inhibition of UCP2 expression in Hep3B cells was due to methylation of the promoter region. Investigating the mechanism that induces UCP2 expression in cancer cells is important to understand the function of UCP2, which could aid in cancer treatment.     

CDH1基因启动子甲基化在上皮性卵巢癌转移方面的研究

目的探讨CDH1基因启动子甲基化对上皮性卵巢癌转移的影响。方法采用免疫组织化学方法检测38例正常卵巢上皮和80例上皮性卵巢癌组织中E-钙黏附素（E-cadherin）表达;应用甲基化特异的PCR（MSP）检测上述组织中CDH1基因启动子区甲基化;应用5-氮-2＇-脱氧胞苷（5-aza-CdR）使SKOV3细胞去甲基化,观察SKOV3细胞体外侵袭性的改变,并通过RT-PCR检测CDH1基因的改变。结果E-cadherin在正常卵巢组织中表达明显高于上皮性卵巢癌（P〈0．05）。34例CDH1基因启动子区甲基化全部出现在卵巢癌组织中,有淋巴结转移组织中甲基化明显高于无淋巴结转移者（P〈0．05）,而CDH1基因启动子区有甲基化的卵巢癌组织中E-cadherin表达明显降低（P〈0．05）。经5-Aza-CdR处理后的SKOV3细胞体外侵袭性降低（P〈0．01）,CDH1基因的表达明显上调（P〈0．01）。结论E-cadherin表达降低与上皮性卵巢癌转移关系密切,CDH1基因启动子区甲基化可能是导致E-cadherin蛋白表达减低的重要原因之一,因此启动子区甲基化与上皮性卵巢癌转移有关。     

Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification

Colorectal cancer (CRC) that demonstrates microsatellite instability (MSI) is caused by either germline mismatch repair (MMR) gene mutations, or 'sporadic' somatic tumour MLH1 promoter methylation. MLH1 promoter methylation is reportedly correlated with tumour BRAF V600E mutation status. No systematic review has been undertaken to assess the value of BRAF V600E mutation and MLH1 promoter methylation tumour markers as negative predictors of germline MMR mutation status. A literature review of CRC cohorts tested for MMR mutations, and tumour BRAF V600E mutation and/or MLH1 promoter methylation was conducted using PubMed. Studies were assessed for tumour features, stratified by tumour MMR status based on immunohistochemistry or MSI where possible. Pooled frequencies and 95% CIs were calculated using a random effects model. BRAF V600E results for 4562 tumours from 35 studies, and MLH1 promoter methylation results for 2975 tumours from 43 studies, were assessed. In 550 MMR mutation carriers, the BRAF V600E mutation frequency was 1.40% (95% CI 0.06% to 3%). In MMR mutation-negative cases, the BRAF V600E mutation frequency was 5.00% (95% CI 4% to 7%) in 1623 microsatellite stable (MSS) cases and 63.50% (95% CI 47% to 79%) in 332 cases demonstrating MLH1 methylation or MLH1 expression loss. MLH1 promoter methylation of the 'A region' was reported more frequently than the 'C region' in MSS CRCs (17% vs 0.06%, p<0.0001) and in MLH1 mutation carriers (42% vs 6%, p<0.0001), but not in MMR mutation-negative MSI-H CRCs (40% vs 47%, p=0.12). Methylation of the 'C region' was a predictor of MMR mutation-negative status in MSI-H CRC cases (47% vs 6% in MLH1 mutation carriers, p<0.0001). This review demonstrates that tumour BRAF V600E mutation, and MLH1 promoter 'C region' methylation specifically, are strong predictors of negative MMR mutation status. It is important to incorporate these features in multifactorial models aimed at predicting MMR mutation status.     

DAPK和DNMT1在宫颈癌中的相关性研究

目的 探讨宫颈癌中DAPK(Death-associated protein kinase)启动子甲基化与DNMT1 mRNA的表达及两者之间的关系.方法 应用甲基化特异性PCR(methylation-specific PCR,MSP)技术检测52例宫颈癌、60例CIN(cervical intraepithelialneoplasia)和20例正常宫颈组织中DAPK启动子甲基化状况;应用原位杂交方法检测DNMT1 mRNA的表达.结果 正常宫颈鳞状上皮不存在DAPK基因启动子CpG岛甲基化,而在CIN和宫颈癌中的甲基化率分别为18.3%(11160)、65.4%(34152),差异有统计学意义(x2=39.639,P＜0.001).正常宫颈鳞状上皮、CIN和宫颈癌DNMT1 mRNA阳性率分别为10%、63.3%和78.8%,差异有统计学意义(x2=29.057,P＜0.001).DAPK异常甲基化和DNMT1 mRNA表达成正相关,r=0.308,P＜0.001.结论 DAPK异常甲基化和DNMT1 mRNA过表达参与了宫颈癌的发生;DAPK基因启动子的甲基化过程可能是在DNMT1的催化作用下完成的.     

启动子DNA甲基化调节胃癌中PDX1基因表达

目的明确PDXl启动子DNA甲基化,探讨启动子甲基化对PDXl在胃癌中表达的调节作用。方法收集3例胃癌活检组织,免疫组化检测PDXl蛋白表达：吉西他滨处理3株胃癌细胞,RT—PCR检测不同药物剂量和作用时间下PDXlmRNA表达;构建PDXl报告基因,检测启动子活性及吉西他滨处理前后启动子活性的变化;甲基化特异性PCR（MSP）检测3株胃癌细胞和8对配对胃癌组织中PDXl启动子甲基化状态。结果免疫组化结果显示胃癌中PDXl表达低于正常胃黏膜;RT—PCR显示吉西他滨使PDXlmRNA重获表达,且随剂量和时间依赖性。F383有最强启动子活性,吉西他滨显著增加了PDXl启动子活性（P〈0．05）。F383在AGS、BCG823、SGC7901中呈DNA完全甲基化状态;87．5％的胃癌组织出现F383部分甲基化,12．5％出现完全甲基化。癌旁正常组织仅有37．5％出现F383部分甲基化,未出现完全甲基化,两者比较有显著性差异（P〈0．05）。结论PDXl启动子存在DNA高甲基化,抑制了胃癌中PDXl的表达。     

Fibulin-1基因启动子区域甲基化与食管癌的关系研究

目的:检测食管癌Fibulin-1基因启动子区域甲基化的情况,探讨其相关的临床意义.方法:选取黄石市中心医院2014年1月至2016年2月收治的食管鳞状细胞癌患者96例,另取同期黄石市中心医院因食管良性病变手术切除的食管组织40例作为对照.Fibulin-1基因启动子甲基化使用亚硫酸盐修饰后PCR检测.免疫组织化学检测显示Fibulin-1蛋白表达.结果:食管癌患者中Fibulin-1基因启动子甲基化阳性率为36.5％,显著高于对照组的15.0％(x2=2.517,P=0.036).免疫组织化学检测显示Fibulin-1基因启动子甲基化标本中Fibulin-1蛋白阳性表达率为90.2％.食管癌患者男女性别和不同年龄之间Fibulin-1基因启动子甲基化率无显著性差异(P＞0.05).Ⅲ,Ⅳ临床分期患者Fibulin-1基因启动子甲基化率为43.1％,显著高于Ⅰ,Ⅱ临床分期患者的28.9％(x2=2.426,P=0.046).肿瘤有淋巴结转移患者Fibulin-1基因启动子甲基化率为44.4％,显著高于无淋巴结转移患者的26.2％(x2=2.438,P=0.041).肿瘤中、低分化患者Fibulin-1基因启动子甲基化率为42.6％,显著高于高分化患者的25.7％(x2=2.431,P=0.043).结论:Fibulin-1基因启动子在食管癌组织中高甲基化,Fibulin-1基因启动子高甲基化与食管癌的临床分期、肿瘤分化程度以及有无淋巴结转移密切相关.